| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1002/(SICI)1098-2388(199910/11)17:3<181::AID-SSU7>3.0.CO;2-7 |
| P698 | PubMed publication ID | 10504666 |
| P2093 | author name string | Thigpen JT | |
| Herrin VE | |||
| P2860 | cites work | Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease | Q28324437 |
| Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer | Q33364853 | ||
| Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group | Q33364857 | ||
| Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients | Q33490971 | ||
| Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study | Q33501657 | ||
| Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials | Q34027970 | ||
| The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study | Q35611986 | ||
| The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer | Q36714706 | ||
| Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report | Q38465480 | ||
| Controversial issues in the management of early epithelial ovarian cancer: conservative surgery and role of adjuvant therapy | Q40579743 | ||
| Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer | Q40673230 | ||
| Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer | Q40705982 | ||
| Sequences of taxol and cisplatin: a phase I and pharmacologic study | Q40745613 | ||
| Surgical staging and cytoreductive surgery of epithelial ovarian cancer. | Q40875091 | ||
| Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma | Q42070597 | ||
| Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma | Q42242398 | ||
| Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. | Q45976411 | ||
| Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. | Q50512108 | ||
| A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA). | Q50558897 | ||
| Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomized trial. | Q53426924 | ||
| Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. | Q54196081 | ||
| Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel | Q57265736 | ||
| Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group | Q67903830 | ||
| Improved prognosis of ovarian cancer in The Netherlands during the period 1975-1985: a registry-based study | Q68008564 | ||
| A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study | Q68864354 | ||
| Dose intensity analysis of chemotherapy regimens in ovarian carcinoma | Q68995715 | ||
| Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms | Q69372459 | ||
| Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study | Q69966311 | ||
| Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease | Q71572038 | ||
| The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma | Q72382597 | ||
| Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer | Q72729402 | ||
| Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer | Q73443071 | ||
| P433 | issue | 3 | |
| P921 | main subject | ovarian cancer | Q172341 |
| chemotherapy | Q974135 | ||
| P304 | page(s) | 181-188 | |
| P577 | publication date | 1999-10-01 | |
| P1433 | published in | Journal of Surgical Oncology | Q1919535 |
| P1476 | title | Chemotherapy for ovarian cancer: current concepts | |
| P478 | volume | 17 |
| Q34651521 | Applications of SKY in cancer cytogenetics |
| Q35269409 | BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival |
| Q39392319 | BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatin |
| Q43781867 | Drug-drug interactions arising from the use of liposomal vincristine in combination with other anticancer drugs |
| Q33349413 | High-dose whole abdominal and pelvic irradiation for treatment of ovarian carcinoma: long-term toxicity and outcomes |
| Q36072797 | In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival. |
| Q84910382 | The role of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis in recurrent ovarian cancer |
| Q36987501 | Treatment of peritoneal carcinomatosis from ovarian cancer. Present, future directions and proposals |
Search more.